Value-Based Pharmaceutical Contracts: Value for Whom?
Feb 1, 2020, 00:00 AM
10.1016/j.jval.2019.10.009
https://www.valueinhealthjournal.com/article/S1098-3015(19)35181-2/fulltext
Section Title :
COMMENTARY
Section Order :
154
First Page :
154
Value-based pharmaceutical contracts (VBPCs) are performance-based reimbursement agreements between healthcare payers and pharmaceutical manufacturers in which the price, amount, or nature of reimbursement is tied to value-based outcomes. VBPCs are often complex, and the nature of who benefits and in what ways can be unclear. We discuss how VBPCs compare with value-based payer–provider arrangements in terms of performance-based reimbursements and alignment of incentives. In addition, we examine how VBPCs can affect costs, clinical outcomes, and access to medications. Because these contracts are unlikely to reduce costs in isolation, we recommend taking a patient-centered approach when developing VBPCs and tying VBPCs to more overarching payer drug cost reduction strategies.
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)35181-2&doi=10.1016/j.jval.2019.10.009
HEOR Topics :
- Health Policy & Regulatory
- Insurance Systems & National Health Care
- Pricing Policy & Schemes
- Reimbursement & Access Policy